Clinical Resources

Contact

For non-emergent questions and concerns related to the virus:

Disclaimer: This website and its content is intended as a resource for clinicians caring for critically-ill COVID-19 patients, based on available evidence and recommendations of governing bodies. The recommendations do not replace clinical judgment or the need for individualized patient care plans. While we attempt to keep this website up-to-date, the literature on COVID-19 is rapidly evolving, and we suggest that practitioners search for the most up-to-date literature on any specific topic. These guidelines will also rapidly evolve as they are implemented into clinical practice and we receive feedback from practitioners. Additionally, local factors should be taken into account if utilized.
 

Updates Included (read on to learn more):

  • Virus statistics and hot spots
  • Rapid decay of COVID-19 antibodies
  • Hydroxychloroquine remains ineffective
  • Vaccine trials
Virus Statistics and Hot Spots
Patient Impact of COVID-19 in U.S.
Active Cases Deaths Recovered
4,919,148 160,335 (3.2%) 2,482,909
*totals as of August 5, 2020
Places with highest daily reported cases per capita

Daily new reported cases per 100,000 residents as of August 5

  • Louisiana: 49 cases (+29% in past week)
  • Nevada: 37 cases (+5%)
  • Texas: 32 (+23%)
  • Mississippi: 32 (-25%)
  • Alabama: 32 (-5%)
  • Florida: 29 (-38%)
Rapid Decay of COVID-19 Antibodies
  • A New England Journal article indicates that re-infection may be possible, especially with those who had mild cases.
  • The study found an antibody half-life of approximately 36 days over the observation period.
  • Results call for caution regarding antibody-based “immunity passports,” herd immunity, and perhaps vaccine durability, especially in light of short-lived immunity against common human coronaviruses.
  • More research is needed.
Hydroxychloroquine Remains Ineffective
  • Due to frequent discussion of hydroxychloroquine online and in the media, many doctors have received questions about the efficacy of the drug.
  • A study concluded on July 23 found that among patients hospitalized with mild-to-moderate COVID-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care
  • This article suggests some strategies for combatting misinformation and addressing false claims from patients.
Vaccine Trials

Click here for information about COVID-19 vaccine trials.